



**Dr. Reddy's Laboratories Ltd.**

8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: [mail@drreddys.com](mailto:mail@drreddys.com)

Web: [www.drreddys.com](http://www.drreddys.com)

December 31, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

**Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that Dr. Reddy's Laboratories SA, Switzerland, wholly owned subsidiary of the Company ("Dr. Reddy's Swiss") has received a Complete Response Letter (CRL) from the United States Food and Drug Administration (USFDA) for its Biologics License Application (BLA) for AVT03 (denosumab), a proposed biosimilar candidate to Prolia® & Xgeva®, developed by Alvotech hf ("Alvotech"). The CRL refers to the observations from a pre-license inspection of Alvotech's Reykjavik manufacturing facility.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*